A tiny a-MSH-derived peptide used for gut and skin inflammation, valued for calming inflammation without broad immunosuppression. Here’s what the (mostly preclinical) evidence supports, the 2026 regulatory status, and the honest caveats.
The one-sentence version: KPV is a small, mechanistically attractive anti-inflammatory peptide used mostly for gut inflammation; the preclinical results are encouraging and it’s on the July 2026 PCAC docket, but human evidence, dosing, and long-term safety are not established — so it’s a promising idea, not a proven treatment.
KPV is a tripeptide — just three amino acids (lysine-proline-valine) — that forms the C-terminal tail of a-MSH (alpha-melanocyte-stimulating hormone), and it appears to carry a-MSH’s anti-inflammatory activity in a small, more stable package. It is used off-label and gray-market mainly for gastrointestinal inflammation (IBD, colitis, “leaky gut”) and sometimes topically or systemically for skin inflammation.
KPV appears to reduce inflammatory signaling inside cells — including the NF-kB pathway central to many inflammatory processes — and, importantly, to do so without broadly suppressing the immune system the way some anti-inflammatory drugs do. Because the peptide is small and reportedly stable in the gut, it’s often taken orally for GI-localized effects, a rationale similar to the case for oral BPC-157 (see the BPC-157 guide).
In laboratory and animal studies, KPV shows anti-inflammatory and gut-healing effects, particularly for colitis and intestinal inflammation. The mechanistic story is coherent and the preclinical signal is real.
Limited — human clinical data is sparseThe gap is human evidence: there’s little controlled clinical trial data in people, no established dosing, and limited long-term safety information. Encouraging in a dish and in mice is not the same as proven in humans — a distinction the marketing tends to blur.
If you have IBD, colitis, or another diagnosed inflammatory condition, that’s a reason to work with a gastroenterologist, not to self-treat with an unapproved peptide — effective, monitored treatments exist, and untreated gut inflammation has real consequences.
KPV is not FDA-approved. It was removed from the FDA’s Category 2 list in April 2026 and is one of the seven peptides on the July 23–24, 2026 PCAC docket for the 503A compounding list — so its US status may change. See our research peptide legal status guide.
KPV is one of the more genuinely interesting anti-inflammatory peptides — small, mechanistically sensible, and non-immunosuppressive, with encouraging preclinical data for gut inflammation. But “encouraging preclinical” is exactly where it sits: the human evidence isn’t there yet, dosing and long-term safety are unestablished, and a real inflammatory condition deserves real medical care. Treat KPV as a promising research peptide to watch (especially through the PCAC process), not a proven therapy.
A small anti-inflammatory peptide used mainly for gut inflammation (IBD, colitis, leaky gut) and sometimes skin. Off-label/gray-market; appeal is anti-inflammatory without broad immunosuppression.
It’s an a-MSH fragment that reduces inflammatory signaling (including NF-kB), and is small/gut-stable so it’s often taken orally for GI use.
Encouraging in cell and animal studies for gut inflammation; limited human clinical data, no established dosing.
Not FDA-approved; sold “research use only.” Removed from Category 2 in April 2026 and on the July 2026 PCAC docket — see the legal-status guide.
Generally described as well tolerated in preclinical work, but human safety data is limited and gray-market purity is unverified. Diagnosed conditions warrant a clinician.
This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. KPV is not FDA-approved and is not a proven treatment for any condition; diagnosed inflammatory or gastrointestinal conditions should be managed with a licensed clinician. Research peptides sold “for research use only” are not approved for human use. Verify current information before relying on it. Current as of June 20, 2026.